source
- Novartis' experimental heart drug pelacarsen fails pivotal Phase 3 trialNovartis announced that its experimental cardiovascular therapy, pelacarsen, did not meet its primary endpoints in the Phase 3 HORIZON trial. The study compared the drug to placebo and found no red…
- Experts say Angelman syndrome drug failure leaves hope for similar antisense therapiesUltragenyx announced that its late-stage trial of an experimental Angelman syndrome drug did not meet its primary endpoints, marking a setback for the rare-disease community. Researchers such as M…